PT41-10 — PT-141
PT-141 (Bremelanotide) is a melanocortin receptor agonist studied for its effects on sexual arousal and desire pathways in the central nervous system — the first peptide formally acknowledged by the FDA for hypoactive sexual desire disorder.
Activates MC3R and MC4R receptors in the hypothalamus, engaging the brain's arousal pathways directly rather than the vascular mechanisms targeted by traditional approaches. Studied in both male and female research models.
Key Benefits
- Central nervous system arousal pathway
- Effective independent of vascular response
- Studied in both male and female models
- Non-hormonal mechanism
- Onset within hours of administration
⚠️ Not approved by FDA for any use, in active clinical trials. FOR RESEARCH ONLY!
Disclaimer
For research purposes only. Not for human or animal use and not FDA-approved. By purchasing, you confirm that you are 21 years of age or older and are a qualified researcher.
Safety and Compliance Statement
This material is intended solely for research purposes under the guidance of qualified professionals. GHK-CU is not approved for human or animal consumption and should be handled with appropriate caution, following established laboratory protocols. Users are advised to conduct experiments in compliance with institutional regulations and safety standards.
For research use only. Not for human or animal consumption.
